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meta-analysis of seroprevalence
surveys of ebolavirus infection
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Asymptomatic ebolavirus infection could greatly inﬂuence transmission dynamics, but there is little
consensus on how frequently it occurs or even if it exists. This paper summarises the available evidence
on seroprevalence of Ebola, Sudan and Bundibugyo virus IgG in people without known ebolavirus
disease. Through systematic review, we identiﬁed 51 studies with seroprevalence results in sera
collected from 1961 to 2016. We tabulated ﬁndings by study population, contact, assay, antigen and
positivity threshold used, and present seroprevalence point estimates and 95% conﬁdence intervals.
We classiﬁed sampled populations in three groups: those with household or known case-contact; those
living in outbreak or epidemic areas but without reported case-contact; and those living in areas with
no recorded cases of ebolavirus disease. We performed meta-analysis only in the known case-contact
group since this is the only group with comparable exposures between studies. Eight contact studies
ﬁtted our inclusion criteria, giving an overall estimate of seroprevalence in contacts with no reported
symptoms of 3.3% (95% CI 2.4–4.4, Po0.001), but with substantial heterogeneity.
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Introduction
Knowing if ebolavirus infection manifests asymptomatically is critical to understanding its spread and to
estimating the role herd immunity could have in reducing transmission. Investigating unrecognised
infections could also help in the development and targeting of vaccines. However, despite a surprisingly
large number of investigations into the seroprevalence of ebolavirus IgG since the ﬁrst outbreak in
Yambuku, Zaire (now Democratic Republic of Congo)1–51, consensus on results has proved elusive. The
main reasons for this are the range of ﬁndings, positive results in unexpected locations, and a lack of
conﬁdence in immunoﬂuorescence antibody (IFA) tests used in early studies.
Concerns about IFA speciﬁcity stem largely from studies showing positive results in populations
expected to be negative, although the most frequently cited—in 200 Panamanian Indians with no known
exposure—found only one Ebola virus IgG positive on a high cut-off giving a speciﬁcity of 99.5%4.
Unexpected seropositivity has also been seen in African countries without reported cases of ebolavirus
disease (EVD) such as the Central African Republic, Cameroon and Zimbabwe, only some of which can
be attributed to using low test cut-offs. But, as some ELISA-based studies have produced similar
ﬁndings37,38, these positive results may indicate zoonotic exposure with ﬁloviruses or unrecognised
human-to-human transmission rather than poor speciﬁcity.
‘Asymptomatic’ status can only be deﬁned for a certain period, such as during an outbreak, though
excluding mild symptoms is difﬁcult. In outbreak areas asymptomatic subjects could have experienced
unrecognised symptomatic EVD in the past so, even apart from problems with the test, ebolavirus
antibody seropositivity does not necessarily mean asymptomatic infection.
We aimed to provide an up-to-date and easily accessible overview of serological ﬁndings to date, to
help researchers contextualise studies prompted by the 2014–16 West Africa epidemic. The most
comprehensive review of ebolavirus serology—Kuhn’s Filoviruses: A Compendium of 40 years of
Epidemiological, Clinical and Laboratory Studies52—covers work to 2008. In addition to reviewing this
key reference, we carried out a systematic review of serosurveys in people without symptoms of EVD up
to July 2016.
Results
Characterisation of seroprevalence surveys of IgG antibodies to ebolavirus
We identiﬁed 51 studies covering 84 sample populations reported to have had no symptoms of EVD
during the outbreak period, or to have come from populations with no known outbreaks. In total these
studies investigated the presence of ebolavirus IgG in 44,147 subjects using samples collected since 1961.
Thirteen studies reported 16 study populations involving 2,664 participants with household or
known case-contact5–7,9,12,36,41,42,45,47,49–51. Eleven studies reported 17 study populations covering 5,327
participants living in outbreak areas but without reported case-contact5–7,9,14,33,39,40,42,43,46. The
remaining studies reported on 51 groups involving 36,156 subjects from general populations, often in
settings ecologically similar to ebolavirus outbreak areas but without known cases of
EVD1–3,5,8,10,11,13,15–35,37,38,44–46,48,51.
Table 1 (available online only) gives a detailed breakdown of the study populations, test methods and
results.
Overall estimates of ebolavirus seroprevalence in asymptomatic individuals
Only the group with known case-contact had exposures that are comparable across studies and are
therefore appropriate to combine by meta-analysis. In this group eight study populations fulﬁlled the
inclusion criteria of testing by ELISA or using a IFA cut-off ≥1:64 (ref. 5,36,41,42,47,49–51). Pooling
these results gave an overall estimate of seroprevalence in asymptomatic people with known case-contact
of 3.3% (95% CI 2.4–4.4, Po0.001), but with substantial heterogeneity due to three small studies with
higher estimates.
In the other two categories—participants living in outbreak areas but without reported case-contact
exposure and general populations in areas without known cases of EVD—exposure was either not well
characterised or not well known. Even where EVD cases had not been reported, zoonotic exposure or
different forms of disease manifestation could not be ruled out. The highly heterogeneous nature of these
study populations makes any single summary estimate inappropriate. In outbreak areas estimates ranged
from 0.9 to 17%, and in general populations described as unexposed estimates ranged from 0 to 24%.
Evidence of assay validation
Few teams reported any validation of the assays used. Some studies repeated analyses with the same
technique, usually in a US or European laboratory, but only seven of the 51 studies reported validation
work through a different diagnostic platform. Of these, two retested a proportion of IFA positives against
ELISA, ﬁnding close to 100% consensus26,30. Three tested ELISA against western blot of which two found
100% speciﬁcity38,46,53; the third did not report results41. Another found 77 and 75% speciﬁcity for ELISA
against western Blot and IFA respectively34, and a further study conﬁrmed IFA results by western blot but
did not report results33.
Two studies in Sierra Leone included ﬁeld testing of ELISA assays in PCR-conﬁrmed positive samples
from EVD survivors and community controls with no known exposure to EVD cases from the research
area. One, using a novel IgG-capture ELISA54, found 95.9% (95%CI 89.9–98.9%) sensitivity and 100%
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speciﬁcity (95%CI 98.9–100%) using oral ﬂuid samples from 97 survivors and 339 community controls51.
The other, using the commercially available ALPHA Diagnostics assay, selected a cut-off that gave
96.7% sensitivity and 97.7% speciﬁcity in serum samples from 30 survivors and 132 community
controls50.
Discussion
We identiﬁed 51 studies covering 84 sample populations of 44,147 subjects reported to have had no
symptoms of EVD during the outbreak period or to come from populations with no known outbreaks.
Most data originated from Western and Middle Africa, and were collected during epidemiological
investigations around outbreaks, or in serosurveys in countries without outbreaks but with similar
ecology and animal hosts, which aimed to map the geographical extent of the virus. Some studies
reported retrospective analysis of samples collected for other reasons prior to the ﬁrst known outbreak
in 1976.
An important ﬁnding of our review is the extreme heterogeneity of the studied populations and the
lack of clarity in describing their exposure levels. We found that while some studies characterised their
sample population clearly by level of contact and presence of symptoms, in many the level of contact/
exposure was less clear, and some did not separate results for symptomatic and asymptomatic subjects.
This makes comparison of results difﬁcult, and combining results from the majority of the studies
impossible. It may also explain the wide variation of ﬁndings which have perplexed investigators
over time.
Many studies also employed very different cut-offs to deﬁne seropositivity meaning a simple review of
results can be misleading. For our analysis, we excluded any study that used a cut off below≥ 1:64 for the
studies using IFA, based on the advice in the literature, but there is no deﬁnitive evidence that this is an
appropriate threshold. The cause of low IFA titre and whether it reﬂects false positives, or waning
antibody response resulting from historical infection which may or may not have been symptomatic, has
been frequently discussed. Recently 10 of 12 survivors from Yambuku were reported to have varying
degrees of EBOV GP and NP reactivity by ELISA, 40 years after the outbreak55. Other studies have shown
positive ELISA results in survivors up to 11 years after infection, but neither reported IFA results for
comparison56.
There is no international reference measurement procedure for ebolavirus antibodies and the World
Health Organisation has acknowledged the urgent need for one. Interestingly, given the scepticism often
expressed regarding the speciﬁcity of IFA techniques in ebolavirus serology, a WHO collaborative study
undertaken in 2015 to identify an interim reference standard found IFA no less speciﬁc or sensitive than
the other methods employed, but only a few samples were tested57.
There are several limitations to the work presented here. The full information necessary for precision
or clear interpretation was often not available. To pursue as high quality research as possible, we have
focussed on publications that have undergone peer review and did not search grey literature. With the
exception of Kuhn et al.52, which has been the standard reference on ﬁlovirus seroprevalence surveys to
date, we did not search books. In addition to the limitations of the studies themselves noted above and in
Table 1, we also note that the distinction of symptomatic and asymptomatic in the papers relied on self-
reported health status, which may not be reliable.
To conclude, we present here a comprehensive updated review of seroprevalence surveys for
ebolavirus infection in order to better understand the variation in rates found. We highlight the
urgent need for validated standardised assays and for detailed characterisation of study population
exposures to enable more generalizable estimates of the extent of asymptomatic ebolavirus infection to
be made.
Methods
Search strategy and systematic review
A systematic search was done in PubMed to identify peer-reviewed papers presenting original data on
ebolavirus infection seroprevalence using the following search string:
ebola AND (asymptom* OR antibod* OR IgG OR immun* OR ELISA OR serol*) NOT vacc* NOT
immuniz* AND (Humans[Mesh])
No limitations were placed on language or location of study. Reference lists of the most comprehensive
review to date52 and other papers were also reviewed. Although the focus of interest was data on subjects
reported not to have symptoms at the time of an outbreak, we included papers reporting seroprevalence
in all populations apart from those with diagnosed EVD in the initial review to ensure relevant studies
were not missed.
The search produced 355 citations which were reviewed by title and abstract. Inclusion criteria
were: investigation of any African species of ebolavirus immunoglobulin G (ie. not Reston) in
individuals without ebolavirus symptoms or in general population groups, with information on
denominators and seropositivity and description of those tested. The same search but limited to 2008
to 2016 was rerun on Web of Science; references prior to 2008 were checked against Kuhn et al’s list52.
Four additional citations were found on Web of Science but none were retained for detailed reading.
Six citations for papers not already included were identiﬁed from reference lists and retained for
detailed reading.
www.nature.com/sdata/
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Total citations: 365 of which 297 (81%) discarded for the following reasons:
● Detailed immunology or genetics with no relevant data collection for seroprevalence
● Description of acute phase diagnosis and/or investigation of convalescent subjects
● Epidemiology and/or treatment of symptomatic conﬁrmed cases without investigation of non-case
populations
● Investigations on sample populations without identiﬁable non-symptomatic individuals
● Studies examining immune response related to vaccination trials
● Review/comment articles without original data
● Modelling papers without original data
● Preliminary or duplicate reports of the same research study/data.
Sixty-eight papers were read in detail after which a further 20 were discarded for the reasons above.
Data extracted from the remaining 48 papers included date of sera collection, composition of study
population(s) in terms of exposure, location, selection process and any other deﬁning characteristics,
assay type, technique and antigens used, positivity threshold, number of participants per population type,
number/proportion of IgG positive individuals, and any information on repeatability or test validity.
All selected papers were scrutinised by both authors independently and results discussed and reconciled.
The last search was made on 31 July 2016. Two presentations from the 2016 Conference on
Retroviruses and Opportunistic Infections (CROI, Feb. 2016) and one from the 8th International
Symposium on Filoviruses (Sept. 2016) describing ﬁndings from the 2014–2016 outbreak were also
included. A paper reporting one of the CROI presentations has subsequently been published (Nov 2016)
and is referenced.
Categorisation of exposure
Many of the studies reported results on sub-populations with different exposures. To reduce
heterogeneity for analysis we categorised these sub-populations under three broad headings according
to the extent of exposure: household or known case-contact; living in outbreak areas but without reported
case-contact; and subjects drawn from general populations in locations without known EVD. Where
study populations were reported to include symptomatic cases and gave enough information to identify
these cases, we removed them and recalculated results.
Overall
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Figure 1. Forest plot and meta-analysis of seroprevalence of ebolavirus IgG among contacts of EVD cases
reported to be asymptomatic during the outbreak period. Further details of each included study are given in
Table 1. Legend: Ref: reference number; IFA: Immunoﬂuorescence Assay; ELISA: Enzyme-linked
immunosorbent assay; ES: Estimated proportion; N, NW: North, Northwestern; SL: Sierra Leone; W. Area:
Western Area Province. Note: Zaire now Democratic Republic of Congo; Rhodesia now Zimbabwe.
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We excluded one study of PCR negative ‘suspects’ with close, no or unknown contact exposure due to
lack of information on symptom status58. In two other studies, sub-groups were not included in the table
because they were reported to include symptomatic cases but gave insufﬁcient information to allow
recalculation of the seroprevalence estimate excluding those with symptoms1,18.
Interpretation of seropositivity
We have recorded seropositivity results by antigen species where reported; where results were not
reported by species, we record positivity to ‘ebolaviruses’. ‘Overall’ positivity is noted where it was
reported or where it was possible to rule out double-counting.
To expose the problem of the different positivity thresholds used, we have recorded all studies and
their reported cut-off in Table 1. Study characteristics and results have also been formatted as a machine-
readable open access dataset (Data Citation 1).
Data visualisation
To summarise the data visually and present 95% conﬁdence intervals, we created Forest plots for each of
the three exposure categories (Figs 1,2,3) which allow results to be compared in the different contact
groups. To address the problem of varying thresholds, we included only those IFA studies that reported
results according to the 1:64 titre cut-off cited as more stringent by WHO and others5,18,21,59, or which
reported enough detail for this threshold to be applied. For ELISA studies, the range of methods used to
deﬁne positivity was too wide to assign a common threshold so all have been included in the Forest plots,
with their method of deﬁning the cut-off detailed in Table 1 (available online only).
Statistical analyses
We performed a meta-analysis using the Freeman Tukey arcsine square root transformation method and
‘ﬁxed effects’ (weighted average) inverse variance (metaprop, STATA60) on the eight study populations
with known-case contact. We chose a ‘ﬁxed effects’ (weighted average) model as contact should give
ELISA
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Kikwit, Zaire 1995 (35)
NE. Gabon 1997 (43)
Location
NE. Gabon 1980 (14)
IFA
236
184
180
205
400
362
448
230
975
Total
253
23
4
12
34
8
47
4
5
10
Positive
9
9.7 (6.3, 14.3)
2.2 (0.6, 5.5)
6.7 (3.5, 11.4)
16.6 (11.8, 22.4)
2.0 (0.9, 3.9)
13.0 (9.7, 16.9)
0.9 (0.2, 2.3)
2.2 (0.7, 5.0)
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Figure 2. Forest plot of seroprevalence of ebolavirus IgG in individuals reported to be asymptomatic
during the outbreak period, recruited in areas with known EVD cases, excluding direct contacts of EVD
cases. Further details of each included study are given in Table 1. Legend: Ref: reference number; ES: Estimated
proportion; IFA: Immunoﬂuorescence Assay ELISA: Enzyme-linked immunosorbent assay; DRC: Democratic
Republic of Congo; N, NE: North, Northeastern.
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similar risks in different contexts, and because random effects models give too much weight to small
studies61. We present an pooled summary estimate for the group with known contact exposure (Fig. 1).
We do not show summary estimates for the groups covering subjects living in outbreak areas but without
reported case-contact, or drawn from general populations in locations without known EVD (Figs 2 and 3)
as these populations are likely to have very different exposure levels so an overall summary estimate of
prevalence would be meaningless.
References
1. Tignor, G. H., Casals, J. & Shope, R. E. The yellow fever epidemic in Ethiopia, 1961-1962: retrospective serological evidence
for concomitant Ebola or Ebola-like virus infection. Transactions of the Royal Society of Tropical Medicine and Hygiene 87,
162 (1993).
2. van der Groen, G. & Pattyn, S. R. Measurement of Antibodies to Ebola Virus in Human-Sera from Nw-Zaire. Annales de la
Societe belge de medecine tropicale 59, 87–92 (1979).
3. Neppert, J., Gohring, S., Schneider, W. & Wernet, P. No Evidence of Lav Infection in the Republic-of-Liberia, West-Africa, in the
Year 1973. Blut 53, 115–117 (1986).
4. van der Groen, G., Johnson, K., Webb, F., Wulff, H, Lange, J. in Ebola Virus Haemorrhagic Fever, edPattyn S. R.)
141–142Elsevier/North-Holland Biomedical Press, (1978).
5. The International Commission. Ebola Haemorrhagic Fever in Zaire. Bulletin WHO (1976).
6. WHO International Study Team. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bulletin
of the World Health Organization 56, 247–270 (1978).
7. Heymann, D. L. et al. Ebola Hemorrhagic Fever: Tandala, Zaire, 1977–1978. Journal of Infectious Diseases 142, 372–376
(1980).
CAR 1979 (10)
N. Rhodesia 1975 (4)
Kono, SL 2015 (50)
Germany 1991 (36)
Location
Gabon 1981-97 (19)
CAR 1987 (30)
ELISA
CAR 1992-5 (38)
CAR 1992-7 (37)
CAR 1992-7 (37)
Sudan  <1984 (23)
Yambuku, Zaire 1976 (5)
IFA
NW. Zaire 1981-85 (18)
NW. Zaire 1972-8 (2)
N. Rhodesia 1980 (15)
CAR 1992-5 (38)
CAR 1987 (30)
Gabon 1985 (24)
CAR 1984-85 (26)
Panama ~1977 (4)
Cameroun 1985 (27)
Siera Leone <1984 (23)
W. Area, SL 2015 (51)
RoC 2011 (48)
Guinea 1982-83 (20)
Benin 1983 (21)
Kikwit, Zaire 1995 (35)
Gabon 2005-08 (46)
Watsa, DRC 2002 (45)
499
243
132
1228
Total
1147
127
683
860
684
284
442
137
251
486
648
300
213
4078
200
375
556
339
809
138
603
161
4349
125
3
0
3
11
Positive
14
31
48
44
48
1
5
2
26
4
23
42
7
335
1
5
20
0
20
2
2
15
667
22
0.6 (0.1, 1.7)
0.0 (0.0, 1.5)
2.3 (0.5, 6.5)
0.9 (0.4, 1.6)
ES (95% CI)
1.2 (0.7, 2.0)
24.4 (17.2, 32.8)
7.0 (5.2, 9.2)
5.1 (3.7, 6.8)
7.0 (5.2, 9.2)
0.4 (0.0, 1.9)
1.1 (0.4, 2.6)
1.5 (0.2, 5.2)
10.4 (6.9, 14.8)
0.8 (0.2, 2.1)
3.5 (2.3, 5.3)
14.0 (10.3, 18.4)
3.3 (1.3, 6.7)
8.2 (7.4, 9.1)
0.5 (0.0, 2.8)
1.3 (0.4, 3.1)
3.6 (2.2, 5.5)
0.0 (0.0, 1.1)
2.5 (1.5, 3.8)
1.4 (0.2, 5.1)
0.3 (0.0, 1.2)
9.3 (5.3, 14.9)
15.3 (14.3, 16.4)
17.6 (11.4, 25.4)
  
0 10 20 30 40
Figure 3. Forest plot of seroprevalence of ebolavirus IgG in general populations living in areas without
reported EVD cases. Further details of each included study are given in Table 1. Legend: Ref: reference
number; IFA: Immunoﬂuorescence Assay; ELISA: Enzyme-linked immunosorbent assay; ES: Estimated
proportion; IFA: Immunoﬂuorescence Assay; ELISA: Enzyme-linked immunosorbent assay; DRC: Democratic
Republic of Congo; RoC: Republic of Congo; CAR: Central African Republic; N, NW: North, Northwestern.
Note: Zaire now Democratic Republic of Congo; Rhodesia now Zimbabwe.
www.nature.com/sdata/
SCIENTIFIC DATA | 4:160133 | DOI: 10.1038/sdata.2016.133 6
8. Knobloch, J., Albiez, E. J. & Schmitz, H. A serological survey on viral haemorrhagic fevers in Liberia. Annales de l'Institut Pasteur/
Virologie 133, 125–128 (1982).
9. Baron, R. C., McCormick, J. B. & Zubeir, O. A. Ebola virus disease in southern Sudan: hospital dissemination and
intrafamilial spread. Bull World Health Organ 61, 997–1003 (1983).
10. Saluzzo, J. F., Gonzalez, J. P., Herve, J. P., Georges, A. J. & Johnson, K. M. Preliminary note on the presence of antibodies to Ebola
virus in the human population in the eastern part of the Central African Republic. Bulletin de la Societe de pathologie exotique et
de ses ﬁliales 73, 238–241 (1980).
11. Bouree, P. & Bergmann, J.-F. Ebola Virus Infection in Man: A Serological and Epidemiological Survey in the Cameroons.
The American Journal of Tropical Medicine and Hygiene 32, 1465–1466 (1983).
12. Smith, D. H. et al. Marburg-Virus Disease in Kenya. The Lancet 319, 816–820 (1982).
13. Johnson, B. K. et al. Antibodies against haemorrhagic fever viruses in Kenya populations. Transactions of the Royal Society of
Tropical Medicine and Hygiene 77, 731–733 (1983).
14. Ivanoff, B. et al. Haemorrhagic fever in Gabon. I. Incidence of Lassa, Ebola and Marburg viruses in Haut-Ogooue. Transactions of
the Royal Society of Tropical Medicine and Hygiene 76, 719–720 (1982).
15. Blackburn, N. K., Searle, L. & Taylor, P. Viral haemorrhagic fever antibodies in Zimbabwe schoolchildren. Transactions of the
Royal Society of Tropical Medicine and Hygiene 76, 803–805 (1982).
16. Talani, P. K., JD., Gromyko, AI., Nanga-Maniane, J., Yala, F. & Bodzongo, D. Prevelence des anticorps anti-ﬁevres hamorragiques
d'origine virale dans la region du Pool (Congo-Brazzaville) Médecine d'Afrique Noire 46 (1999).
17. Van der Waals, F. W., Pomeroy, K. L., Goudsmit, J., Asher, D. M. & Gajdusek, D. C. Hemorrhagic fever virus infections in an
isolated rainforest area of central Liberia. Limitations of the indirect immunoﬂuorescence slide test for antibody screening
in Africa. Tropical and geographical medicine 38, 209–214 (1986).
18. Jezek, Z., Szczeniowski, M. Y., Muyembe-Tamfum, J. J., McCormick, J. B. & Heymann, D. L. Ebola between Outbreaks: Intensiﬁed
Ebola Hemorrhagic Fever Surveillance in the Democratic Republic of the Congo, 1981–1985. Journal of Infectious Diseases 179,
S60–S64 (1999).
19. Lahm, S. A., Kombila, M., Swanepoel, R. & Barnes, R. F. Morbidity and mortality of wild animals in relation to outbreaks of
Ebola haemorrhagic fever in Gabon, 1994-2003. Transactions of the Royal Society of Tropical Medicine and Hygiene 101,
64–78 (2007).
20. Boiro, I. et al. Clinico-epidemiologic and laboratory research on hemorrhagic fevers in Guinea. Bulletin de la Societe de pathologie
exotique et de ses ﬁliales 80 607–612 (1987).
21. Gonzalez, J. P. Ebola Virus Circulation in Africa: a balance between clinical expression and epidemiological silence. Epidemiologie
98, 210–217 (2005).
22. Rodhain, F. et al. Arbovirus infections and viral haemorrhagic fevers in Uganda: a serological survey in Karamoja district, 1984.
Transactions of the Royal Society of Tropical Medicine and Hygiene 83, 851–854 (1989).
23. Slenczka, W., Rietschel, M., Hoffmann, C. & W, S. Seroepidemiologische Untersuchungen über das Vorkommen von Antikörpern
gegen Marburg und Ebola Virus in Afrika. Mitt. Österr. Ges. Tropical Med. Parasitol 6, 53–60 (1984).
24. Meunier, D. M. Y., Dupont, A., Madelon, M. C., Gonzalez, J. P. & Ivanoff, B. Surveillance sérologique des ﬁèvres hémorragiques
virales dans le Haut-Ogooue (Gabon). Annales de l'Institut Pasteur / Virologie 138, 229–235 (1987).
25. Meunier, D. M. et al. Current serologic data on viral hemorrhagic fevers in the Central African Republic. Bulletin de la Societe de
pathologie exotique et de ses ﬁliales 80, 51–61 (1987).
26. Johnson, E. D., Gonzalez, J. P. & Georges, A. Haemorrhagic fever virus activity in equatorial Africa: distribution and prevalence of
ﬁlovirus reactive antibody in the Central African Republic. Transactions of the Royal Society of Tropical Medicine and Hygiene 87,
530–535 (1993).
27. Paix, M. A. et al. Serological study of the virus responsible for hemorrhagic fever in an urban population of Cameroon. Bulletin de
la Societe de pathologie exotique et de ses ﬁliales 81, 679–682 (1988).
28. Gonzalez, J. P. et al. Antibody prevalence against haemorrhagic fever viruses in randomized representative Central African
populations. Research in virology 140, 319–331 (1989).
29. Tessier, S. F., Rollin, P. E. & Sureau, P. Viral haemorrhagic fever survey in Chobe (Botswana). Transactions of the Royal Society of
Tropical Medicine and Hygiene 81, 699–700 (1987).
30. Johnson, E. D., Gonzalez, J. P. & Georges, A. Filovirus activity among selected ethnic groups inhabiting the tropical forest of
equatorial Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 536–538 (1993).
31. Tomori, O., Fabiyi, A., Sorungbe, A., Smith, A. & McCormick, J. B. Viral hemorrhagic fever antibodies in Nigerian populations.
Am J Trop Med Hyg 38, 407–410 (1988).
32. Mathiot, C. C., Fontenille, D., Georges, A. J. & Coulanges, P. Antibodies to haemorrhagic fever viruses in Madagascar populations.
Transactions of the Royal Society of Tropical Medicine and Hygiene 83, 407–409 (1989).
33. US Centers for Disease Control. Update: ﬁlovirus infection associated with contact with nonhuman primates or their tissues.
MMWR. Morbidity and mortality weekly report 39, 404–405 (1990).
34. Becker, S., Feldmann, H., Will, C. & Slenczka, W. Evidence for Occurrence of Filovirus Antibodies in Humans and
Imported Monkeys—Do Subclinical Filovirus Infections Occur Worldwide. Medical microbiology and immunology 181,
43–55 (1992).
35. Busico, K. M. et al. Prevalence of IgG Antibodies to Ebola Virus in Individuals during an Ebola Outbreak, Democratic Republic of
the Congo, 1995. Journal of Infectious Diseases 179, S102–S107 (1999).
36. Rowe, A. K. et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients
and their household contacts, Kikwit, Democratic Republic of the Congo. Journal of Infectious Diseases 179, S28–S35
(1999).
37. Nakounne, E., Selekon, B. & Morvan, J. Microbiological surveillance: viral hemorrhagic fever in Central African Republic: current
serological data in man. Bulletin de la Societe de pathologie exotique (1990) 93, 340–347 (2000).
38. Gonzalez, J. P., Nakoune, E., Slenczka, W., Vidal, P. & Morvan, J. M. Ebola and Marburg virus antibody prevalence in selected
populations of the Central African Republic. Microbes and Infection 2, 39–44 (2000).
39. Georges, A. J. et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. The Journal
of infectious diseases 179(Suppl 1): S65–S75 (1999).
40. Tomori, O. et al. Serologic Survey among Hospital and Health Center Workers during the Ebola Hemorrhagic Fever Outbreak in
Kikwit, Democratic Republic of the Congo, 1995. Journal of Infectious Diseases 179, S98–S101 (1999).
41. Leroy, E. M. et al. Human asymptomatic Ebola infection and strong inﬂammatory response. The Lancet 355, 2210–2215
(2000).
42. Bertherat, E., Renaut, A., Nabias, R., Dubreuil, G. & Georges-Courbot, M. C. Leptospirosis and Ebola virus infection in ﬁve
gold-panning villages in northeastern Gabon. The American Journal of Tropical Medicine and Hygiene 60, 610–615
(1999).
43. Heffernan, R. T. et al. Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooue-Ivindo region,
Northeastern Gabon, 1997. The Journal of infectious diseases 191, 964–968 (2005).
www.nature.com/sdata/
SCIENTIFIC DATA | 4:160133 | DOI: 10.1038/sdata.2016.133 7
44. Vladyko, A. S. et al. False-positive reactions in laboratory diagnosis of Lassa, Marburg, and Ebola viral hemorrhagic fevers
and AIDS. Russian Progress in Virology 2, 25–30 (1997).
45. Mulangu, S. et al. High prevalence of IgG antibodies to Ebola virus in the Efe pygmy population in the Watsa region, Democratic
Republic of the Congo. Bmc Infectious Diseases 16, 263 (2016).
46. Nkoghe, D. et al. Risk factors for Zaire ebolavirus--speciﬁc IgG in rural Gabonese populations. The Journal of infectious diseases
204(Suppl 3): S768–S775 (2011).
47. Clark, D. V. et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. The Lancet
Infectious Diseases 15, 905–912 (2015).
48. Moyen, N. et al. Risk Factors Associated with Ebola and Marburg Viruses Seroprevalence in Blood Donors in the Republic
of Congo. PLoS neglected tropical diseases 9, e0003833 (2015).
49. Fallah, M. & PREVAIL III Research Team. A cohort study of survivors of Ebola Virus Infection in Liberia. Conference on
Retroviruses and Opportunistic Infections (CROI). At: http://www.croiwebcasts.org/console/player/29569?mediaType=slide
Video& (2016).
50. Richardson, E. T. et al. Minimally Symptomatic Infection in an Ebola 'Hotspot': A Cross-Sectional Serosurvey. PLoS neglected
tropical diseases 10, e0005087 (2016).
51. Glynn, J. B. et al. Asymptomatic infection and unrecognised Ebola Virus Disease, Sierra Leone (Filovirus 2016 Symposium,
Antwerp, Belgium (2016).
52. Kuhn, J. H. & Calisher, C. H. Filoviruses: a compendium of 40 years of epidemiological, clinical and laboratory studies. Springer
Science and Business Media, (2008).
53. Becquart, P. et al. High Prevalence of Both Humoral and Cellular Immunity to Zaire ebolavirus among Rural Populations
in Gabon. Plos One 5, e9126 (2010).
54. Lambe, T. et al. Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid. Open forum infectious diseases 3,
ofw031 (2016).
55. Remoin, A. et al. Persistent Immune Response in Ebola Survivors from Yambuku Outbreak 40 years after Infection (Filovirus
2016 Symposium, Antwerp, Belgium (2016).
56. Wauquier, N., Becquart, P., Gasquet, C. & Leroy, E. M. Immunoglobulin G in Ebola outbreak survivors, Gabon. Emerg Infect Dis
15, 1136–1137 (2009).
57. Expert committee on Biological Standardisation. WHO collaborative study to assess the suitability of an interim standard for
antibodies to Ebola virus. Report No. WHO/BS/2015.2280 post-ECBS, (World Health Organisation (2015).
58. de La Vega, M. A. et al. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. The Journal of
clinical investigation 125, 4421–4428 (2015).
59. Pattyn, S. R.. Ebola Virus Haemorrhagic Fever: Proceedings of an International Colloquium on Ebola Virus Infection
and Other Haemorrhagic Fevers held in Antwerp, Belgium, 6-8 December, 1977. Elsevier/North-Holland Biomedical Press,
(1978).
60. Nyaga, V. N., Arbyn, M. & Aerts, M. Metaprop: a Stata command to perform meta-analysis of binomial data. Archives of Public
Health 72, 39 (2014).
61. Higgins J. & Green S.(eds)in The Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0) (The Cochrane
Collaboration).
62. Wulff, H. & Lange, J. Indirect Immunoﬂouresce for the diagnosis of Lassa Fever Infection. Bulletin of the World Health
Organization 52, 429–436 (1975).
63. Johnson, K. M., Elliott, L. H. & Heymann, D. L. Preparation of polyvalent viral immunoﬂuorescent intracellular antigens and use
in human serosurveys. Journal of clinical microbiology 14, 527–529 (1981).
64. Gardner, P. S. & McQuillin, J. Rapid virus diagnosis, application of immunoﬂourescence. (Butterworth & Co, 1974).
65. Bashkirtsev, V. N., Tkachenko, E. A., Dzagurova, T. K. & Ryl'tseva, E. V. Isolation of strains of the virus of hemorrhagic fever with
renal syndrome in cell culture. Voprosy virusologii 29, 497–502 (1984).
66. Emmerich, P. et al. Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections in Africa. Journal of clinical virology
: the ofﬁcial publication of the Pan American Society for Clinical Virology 37, 277–281 (2006).
67. Ksiazek, T. G., West, C. P., Rollin, P. E., Jahrling, P. B. & Peters, C. J. ELISA for the Detection of Antibodies to Ebola Viruses.
Journal of Infectious Diseases 179, S192–S198 (1999).
68. Schoepp, R. J., Rossi, C. A., Khan, S. H., Goba, A. & Fair, J. N. Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerg Infect
Dis 20, 1176–1182 (2014).
69. Boisen, M. L. et al. Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human
exposure to ﬁloviruses in Sierra Leone prior to the 2014 outbreak. Viral immunology 28, 19–31 (2015).
70. Niklasson, B., Peters, C. J., Grandien, M. & Wood, O. Detection of human immunoglobulins G and M antibodies to Rift Valley
fever virus by enzyme-linked immunosorbent assay. Journal of clinical microbiology 19, 225–229 (1984).
71. Rezapkin, G. V., Tkachenko, E. A., Ivanov, A. P., Bashkirtsev, V. N. & Dzagurova, T. K. Determination of arenavirus antigens and
antibodies by solid-phase radioimmunological analysis. Voprosy virusologii 459–462 (1981).
72. Johnson, B. K. et al. Viral haemorrhagic fever surveillance in Kenya, 1980-1981. Tropical and geographical medicine 35,
43–47 (1983).
73. US Centers for Disease Control. Update: evidence of ﬁlovirus infection in an animal caretaker in a research/service facility.
MMWR. Morbidity and mortality weekly report 39, 296–297 (1990).
74. US Centers for Disease Control. Update: ﬁlovirus infections among persons with occupational exposure to nonhuman primates.
MMWR. Morbidity and mortality weekly report 39, 266–267, 273 (1990).
75. Alpha Diagnostic International, I. Zaire-Ebola virus nucleoprotein (EBOV-NP) IgG (AE-320520-1) kit and IgM (AE-320530-1)
ELISA kit product descriptions. http://www.4adi.com/ (2016).
Data Citations
1. Bower, H. & Glynn, J. R. Dryad Digital Repository http://dx.doi.org/10.5061/dryad.gn95r (2016).
Acknowledgements
We acknowledge with thanks the support of the Wellcome Trust’s Enhancing Research Activity in
Epidemic Situations (ERAES) programme (Grant No. ER1502).
Author Contributions
H.B. conceived the review, created the search strategy, retrieved and screened the papers, extracted and
compiled the data, created the graphics, carried out the analysis and drafted the paper. J.R.G. reviewed the
strategy and analysis, checked all data extraction, and contributed to subsequent drafts of the paper.
www.nature.com/sdata/
SCIENTIFIC DATA | 4:160133 | DOI: 10.1038/sdata.2016.133 8
Additional Information
Table 1 is only available in the online version of this paper.
Competing ﬁnancial interests: H.B. and J.R.G. declare they have no competing ﬁnancial interests nor
conﬂicts of interest. Both authors have had had full access to all the data in the study and take
responsibility for the integrity of the data and the accuracy of the data analysis.
How to cite this article: Bower, H. & Glynn, J. R. A systematic review and meta-analysis of
seroprevalence surveys of ebolavirus infection. Sci. Data 4:160133 doi: 10.1038/sdata.2016.133 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps
and institutional afﬁliations.
This work is licensed under a Creative Commons Attribution 4.0 International License. The
images or other third party material in this article are included in the article’s Creative
Commons license, unless indicated otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0
© The Author(s) 2017
www.nature.com/sdata/
SCIENTIFIC DATA | 4:160133 | DOI: 10.1038/sdata.2016.133 9
